Mirati Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mirati Therapeutics generated cash of -$570,570,000, which is less than the previous year. Cash used in financing activities reached the amount of $166,944,000 last year. Net change in cash is therefore -$177,823,000.
Cash Flow
| 2013 | -29.45M | -29.47M | 54.75M |
|---|---|---|---|
| 2014 | -32.74M | 24.21M | 887K |
| 2015 | -50.71M | -50.75M | 144.36M |
| 2016 | -68.01M | 38.25M | 2.65M |
| 2017 | -64.70M | -8.65M | 158.67M |
| 2018 | -70.09M | -145.76M | 140.85M |
| 2019 | -147.72M | -176.14M | 338.02M |
| 2020 | -271.53M | -139.85M | 1.25B |
| 2021 | -388.8M | -588.90M | 505.22M |
| 2022 | -570.57M | 225.80M | 166.94M |
MRTX Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 413.70M | 886.18M | 46.85M | 32.69M | 107.70M | 22.38M | 49.49M | 6.59M | 14.23M | 18.40M |
Operating activities | ||||||||||
Net income | -740.86M | -581.78M | -357.93M | -213.25M | -98.41M | -70.43M | -83.11M | -64.54M | -43.69M | -52.85M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.92M | 1.78M | 641K | 249K | 175K | 184K | 180K | 212K | 199K | 171K |
Stock-based compensation expense | 186.18M | 113.50M | 85.84M | 55.53M | 15.85M | 6.78M | 10.62M | 10.25M | 7.05M | 3.19M |
| Deferred income tax benefit | 186.18M | 113.50M | 85.84M | 55.53M | 15.85M | 6.78M | 10.62M | 10.25M | 7.05M | 3.19M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -865K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -3.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -4.87M | 71.06M | 23.24M | 23.02M | 12.92M | -1.34M | 5.19M | 4.37M | 151K | -68K |
Cash generated by operating activities | -570.57M | -388.8M | -271.53M | -147.72M | -70.09M | -64.70M | -68.01M | -50.71M | -32.74M | -29.45M |
Investing activities | ||||||||||
Purchases Of Investments | -956.70M | -1.42B | -662.82M | -530.22M | -255.79M | -100.55M | -70.26M | -104.95M | -10.46M | -68.40M |
Investments In Property Plant And Equipment | -4.85M | -9.79M | -4.36M | -1.55M | -122K | -81K | -196K | -329K | -386K | -204K |
Acquisitions Net | -230.65M | 579.10M | 135.49M | 174.58M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 225.80M | -588.90M | -139.85M | -176.14M | -145.76M | -8.65M | 38.25M | -50.75M | 24.21M | -29.47M |
Financing activities | ||||||||||
Common Stock Issued | 155.01M | 474.69M | 1.20B | 327.83M | 130.66M | 153.53M | 0 | 143.29M | 0 | 54.19M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 166.94M | 505.22M | 1.25B | 338.02M | 140.85M | 158.67M | 2.65M | 144.36M | 887K | 54.75M |
Net Change In Cash | -177.82M | -472.47M | 839.32M | 14.16M | -75.00M | 85.32M | -27.11M | 42.9M | -7.64M | -4.16M |
Cash at end of period | 235.88M | 413.70M | 886.18M | 46.85M | 32.69M | 107.70M | 22.38M | 49.49M | 6.59M | 14.23M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |